Literature DB >> 19429166

Characterisation of a novel NR4A2 mutation in Parkinson's disease brain.

P M A Sleiman1, D G Healy, M M K Muqit, Y X Yang, M Van Der Brug, J L Holton, T Revesz, N P Quinn, K Bhatia, J K J Diss, A J Lees, M R Cookson, D S Latchman, N W Wood.   

Abstract

OBJECTIVE: We performed a mutation screen of NR4A2 (also known as NURR1) in 409 Parkinson's disease (PD) patients. We identified a novel single base substitution in the 5'UTR of the NR4A2 (also known as NURR1) gene (c.-309C>T).
RESULTS: We have performed expression studies in neuronal cell lines showing that the c.-309C>T mutation reduces NR4A2 mRNA expression in vitro. We have confirmed this finding in vivo by performing allele specific real-time PCR from brain tissue harbouring the 309C>T mutation and show a 3.48+/-1.62 fold reduction in mRNA expression of the mutant allele compared to wild-type. In addition we have undertaken genome wide expression analysis of the mutant NR4A2 brain and shown underexpressed genes were significantly enriched for gene ontology categories in nervous system development and synaptic transmission and overexpressed genes were enriched for unfolded protein response and morphogenesis. Lastly we have shown that the c.-309C>T mutation abrogates the protective effect of wild-type NR4A2 against apoptopic stress.
CONCLUSIONS: Our findings indicate the c.-309C>T mutation reduces NR4A2 expression resulting in the downregulation of genes involved in the development and maintenance of the nervous system and synaptic transmission. These downregulated pathways contained genes known to be transactivated by NR4A2 and were not disrupted in idiopathic PD brain suggesting causality of the mutation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19429166      PMCID: PMC4763922          DOI: 10.1016/j.neulet.2009.03.021

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  25 in total

1.  Absence of NR4A2 exon 1 mutations in 108 families with autosomal dominant Parkinson disease.

Authors:  P Ibáñez; E Lohmann; P Pollak; F Durif; C Tranchant; Y Agid; A Dürr; A Brice
Journal:  Neurology       Date:  2004-06-08       Impact factor: 9.910

2.  Pvclust: an R package for assessing the uncertainty in hierarchical clustering.

Authors:  Ryota Suzuki; Hidetoshi Shimodaira
Journal:  Bioinformatics       Date:  2006-04-04       Impact factor: 6.937

3.  Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from the GenePD study.

Authors:  Samer Karamohamed; L I Golbe; M H Mark; A M Lazzarini; O Suchowersky; N Labelle; Mark Guttman; L J Currie; G F Wooten; M Stacy; M Saint-Hilaire; R G Feldman; J Liu; C M Shoemaker; J B Wilk; A L DeStefano; J C Latourelle; G Xu; R Watts; J Growdon; M Lew; C Waters; P Vieregge; P P Pramstaller; C Klein; B A Racette; J S Perlmutter; A Parsian; Carlos Singer; E Montgomery; K Baker; J F Gusella; A Herbert; R H Myers
Journal:  Mov Disord       Date:  2005-09       Impact factor: 10.338

Review 4.  Genetics of Parkinson disease: paradigm shifts and future prospects.

Authors:  Matthew James Farrer
Journal:  Nat Rev Genet       Date:  2006-04       Impact factor: 53.242

5.  Translated mutation in the Nurr1 gene as a cause for Parkinson's disease.

Authors:  David A Grimes; Fabin Han; Michel Panisset; Lemuel Racacho; Fengxia Xiao; Ruobing Zou; Kelly Westaff; Dennis E Bulman
Journal:  Mov Disord       Date:  2006-07       Impact factor: 10.338

6.  Nurr1 enhances transcription of the human dopamine transporter gene through a novel mechanism.

Authors:  P Sacchetti; T R Mitchell; J G Granneman; M J Bannon
Journal:  J Neurochem       Date:  2001-03       Impact factor: 5.372

7.  Age-dependent dopaminergic dysfunction in Nurr1 knockout mice.

Authors:  Chuantao Jiang; Xinhua Wan; Yi He; Tianhong Pan; Joseph Jankovic; Weidong Le
Journal:  Exp Neurol       Date:  2005-01       Impact factor: 5.330

8.  Nurr1 mutational screen in Parkinson's disease.

Authors:  Eng-King Tan; Henry Chung; Vandana R Chandran; Chris Tan; Hui Shen; Kenneth Yew; Ratnagopal Pavanni; Kathi-avelu Puvan; Meng-Cheong Wong; Mei-Lin Teoh; Yuan Yih; Yi Zhao
Journal:  Mov Disord       Date:  2004-12       Impact factor: 10.338

9.  Mutations in NR4A2 associated with familial Parkinson disease.

Authors:  Wei-Dong Le; Pingyi Xu; Joseph Jankovic; Hong Jiang; Stanley H Appel; Roy G Smith; Demetrios K Vassilatis
Journal:  Nat Genet       Date:  2002-12-23       Impact factor: 38.330

10.  Nurr1, an orphan nuclear receptor, is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain.

Authors:  K Sakurada; M Ohshima-Sakurada; T D Palmer; F H Gage
Journal:  Development       Date:  1999-09       Impact factor: 6.868

View more
  17 in total

Review 1.  NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.

Authors:  Mickael Decressac; Nikolaos Volakakis; Anders Björklund; Thomas Perlmann
Journal:  Nat Rev Neurol       Date:  2013-10-15       Impact factor: 42.937

2.  Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease.

Authors:  Krista McFarland; Tracy A Spalding; David Hubbard; Jian-Nong Ma; Roger Olsson; Ethan S Burstein
Journal:  ACS Chem Neurosci       Date:  2013-10-11       Impact factor: 4.418

3.  Nurr1:RXRα heterodimer activation as monotherapy for Parkinson's disease.

Authors:  Athanasios D Spathis; Xenophon Asvos; Despina Ziavra; Theodoros Karampelas; Stavros Topouzis; Zoe Cournia; Xiaobing Qing; Pavlos Alexakos; Lisa M Smits; Christina Dalla; Hardy J Rideout; Jens Christian Schwamborn; Constantin Tamvakopoulos; Demosthenes Fokas; Demetrios K Vassilatis
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-27       Impact factor: 11.205

Review 4.  The delta-opioid receptor and Parkinson's disease.

Authors:  Jin-Zhong Huang; Yi Ren; Yuan Xu; Tao Chen; Terry C Xia; Zhuo-Ri Li; Jian-Nong Zhao; Fei Hua; Shi-Ying Sheng; Ying Xia
Journal:  CNS Neurosci Ther       Date:  2018-08-03       Impact factor: 5.243

5.  Dopaminergic control of autophagic-lysosomal function implicates Lmx1b in Parkinson's disease.

Authors:  Ariadna Laguna; Nicoletta Schintu; André Nobre; Alexandra Alvarsson; Nikolaos Volakakis; Jesper Kjaer Jacobsen; Marta Gómez-Galán; Elena Sopova; Eliza Joodmardi; Takashi Yoshitake; Qiaolin Deng; Jan Kehr; Johan Ericson; Per Svenningsson; Oleg Shupliakov; Thomas Perlmann
Journal:  Nat Neurosci       Date:  2015-04-27       Impact factor: 24.884

6.  Altered transcription factor trafficking in oxidatively-stressed neuronal cells.

Authors:  Vivek P Patel; Donald B Defranco; Charleen T Chu
Journal:  Biochim Biophys Acta       Date:  2012-08-08

7.  A Wnt1 regulated Frizzled-1/β-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotection.

Authors:  Francesca L'episcopo; Maria F Serapide; Cataldo Tirolo; Nunzio Testa; Salvatore Caniglia; Maria C Morale; Stefano Pluchino; Bianca Marchetti
Journal:  Mol Neurodegener       Date:  2011-07-13       Impact factor: 14.195

8.  The Transcription Factor NURR1 Exerts Concentration-Dependent Effects on Target Genes Mediating Distinct Biological Processes.

Authors:  Magen M Johnson; Sharon K Michelhaugh; Mohamad Bouhamdan; Carl J Schmidt; Michael J Bannon
Journal:  Front Neurosci       Date:  2011-12-20       Impact factor: 4.677

Review 9.  Uncovering novel actors in astrocyte-neuron crosstalk in Parkinson's disease: the Wnt/β-catenin signaling cascade as the common final pathway for neuroprotection and self-repair.

Authors:  Bianca Marchetti; Francesca L'Episcopo; Maria Concetta Morale; Cataldo Tirolo; Nuccio Testa; Salvo Caniglia; Maria Francesca Serapide; Stefano Pluchino
Journal:  Eur J Neurosci       Date:  2013-03-05       Impact factor: 3.386

10.  The N-terminal region of Nurr1 (a.a 1-31) is essential for its efficient degradation by the ubiquitin proteasome pathway.

Authors:  Beatriz Alvarez-Castelao; Fernando Losada; Patrícia Ahicart; Jose G Castaño
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.